Published in Drug Dev Ind Pharm on September 01, 2009
Marine origin collagens and its potential applications. Mar Drugs (2014) 0.87
PLGA-carbon nanotube conjugates for intercellular delivery of caspase-3 into osteosarcoma cells. PLoS One (2013) 0.80
Molecular Cloning, Characterization, and Expression Analysis of a Prolyl 4-Hydroxylase from the Marine Sponge Chondrosia reniformis. Mar Biotechnol (NY) (2015) 0.75
The microstructure of collagen type I gel cross-linked with gold nanoparticles. Colloids Surf B Biointerfaces (2012) 0.75
Molecular characterization of a nonfibrillar collagen from the marine sponge Chondrosia reniformis Nardo 1847 and positive effects of soluble silicates on its expression. Mar Biotechnol (NY) (2011) 0.75
Crystal structure of a soluble CD28-Fab complex. Nat Immunol (2005) 2.46
Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release (2009) 2.09
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med (2005) 1.79
Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med (2003) 1.70
Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol (2006) 1.59
Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer (2004) 1.54
Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm (2004) 1.41
Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release (2011) 1.37
Characterization of mouse CD4 T cell subsets defined by expression of KLRG1. Eur J Immunol (2007) 1.36
Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm (2008) 1.33
CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells. Autoimmun Rev (2005) 1.32
Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in "human immune system" Rag2(-/-)gammac(-/-) mice. Blood (2006) 1.23
First evidence of chitin as a component of the skeletal fibers of marine sponges. Part I. Verongidae (demospongia: Porifera). J Exp Zool B Mol Dev Evol (2007) 1.21
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett (2007) 1.20
Human serum albumin-polyethylenimine nanoparticles for gene delivery. J Control Release (2003) 1.20
First evidence of the presence of chitin in skeletons of marine sponges. Part II. Glass sponges (Hexactinellida: Porifera). J Exp Zool B Mol Dev Evol (2007) 1.19
Fibrillogenesis of collagen types I, II, and III with small leucine-rich proteoglycans decorin and biglycan. Biomacromolecules (2006) 1.16
Lessons from TGN1412. Lancet (2006) 1.16
Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem (2009) 1.11
Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials (2005) 1.10
Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol (2009) 1.09
Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem (2008) 1.08
Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target (2004) 1.08
Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm (2009) 1.06
Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J Drug Target (2010) 1.05
Large-scale production of pharmaceuticals by marine sponges: sea, cell, or synthesis? Biotechnol Bioeng (2005) 1.04
Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLoS One (2012) 1.02
Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One (2011) 0.99
Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials (2005) 0.99
Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target (2006) 0.98
Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target (2010) 0.97
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia (2010) 0.97
Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target (2009) 0.93
Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. J Control Release (2011) 0.93
Nanoparticulate transport of oximes over an in vitro blood-brain barrier model. PLoS One (2010) 0.92
A new metaphyseal bone defect model in osteoporotic rats to study biomaterials for the enhancement of bone healing in osteoporotic fractures. Acta Biomater (2013) 0.92
Novel textile chitosan scaffolds promote spreading, proliferation, and differentiation of osteoblasts. Biomacromolecules (2008) 0.92
Ultrastructural studies on the collagen of the marine sponge Chondrosia reniformis Nardo. Biomacromolecules (2007) 0.92
Marine sponge collagen: isolation, characterization and effects on the skin parameters surface-pH, moisture and sebum. Eur J Pharm Biopharm (2002) 0.90
Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials (2009) 0.90
Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J Control Release (2004) 0.90
Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul (2006) 0.90
Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur J Pharm Biopharm (2010) 0.89
Collageneous matrix coatings on titanium implants modified with decorin and chondroitin sulfate: characterization and influence on osteoblastic cells. J Biomed Mater Res A (2006) 0.88
Ethylcellulose: a new type of emulsion stabilizer. Eur J Pharm Biopharm (2003) 0.88
Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. Int J Pharm (2010) 0.87
Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties, and intracellular distribution. J Control Release (2005) 0.87
Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays. J Drug Target (2006) 0.87
Adsorption of plasma proteins on uncoated PLGA nanoparticles. Eur J Pharm Biopharm (2013) 0.87
Oligonucleotide-protamine-albumin nanoparticles: Protamine sulfate causes drastic size reduction. J Control Release (2005) 0.85
Interactions of collagen types I and II with chondroitin sulfates A-C and their effect on osteoblast adhesion. Biomacromolecules (2007) 0.85
Cultivation of an immortalized human corneal endothelial cell population and two distinct clonal subpopulations on thermo-responsive carriers. Graefes Arch Clin Exp Ophthalmol (2008) 0.85
In vitro ossification and remodeling of mineralized collagen I scaffolds. Tissue Eng (2006) 0.85
Chitin-based renewable materials from marine sponges for uranium adsorption. Carbohydr Polym (2012) 0.84
Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles. Int J Pharm (2011) 0.84
Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. J Control Release (2004) 0.84
Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides. Eur J Pharm Biopharm (2005) 0.84
In vitro evaluation of textile chitosan scaffolds for tissue engineering using human bone marrow stromal cells. Biomacromolecules (2009) 0.84
Modification of Ti6AL4V surfaces using collagen I, III, and fibronectin. II. Influence on osteoblast responses. J Biomed Mater Res A (2003) 0.84
Bioactive silica-collagen composite xerogels modified by calcium phosphate phases with adjustable mechanical properties for bone replacement. Acta Biomater (2009) 0.83
A bioactive triphasic ceramic-coated hydroxyapatite promotes proliferation and osteogenic differentiation of human bone marrow stromal cells. J Biomed Mater Res A (2009) 0.83
Assessment of angiogenesis in osseointegration of a silica-collagen biomaterial using 3D-nano-CT. Acta Biomater (2011) 0.83
Degradation of microvascular brain endothelial cell beta-catenin after co-culture with activated neutrophils from patients undergoing cardiac surgery with prolonged cardiopulmonary bypass. Biochem Biophys Res Commun (2005) 0.83
Adsorption of obidoxime onto human serum albumin nanoparticles: drug loading, particle size and drug release. J Microencapsul (2010) 0.82
Mimicked bioartificial matrix containing chondroitin sulphate on a textile scaffold of poly(3-hydroxybutyrate) alters the differentiation of adult human mesenchymal stem cells. Tissue Eng (2006) 0.82
Are assumptions about the model type necessary in reaction-diffusion modeling? A FRAP application. Biophys J (2011) 0.82
Microparticles derived from marine sponge collagen (SCMPs): preparation, characterization and suitability for dermal delivery of all-trans retinol. Eur J Pharm Biopharm (2002) 0.81
Modification of Ti6Al4V surfaces using collagen I, III, and fibronectin. I. Biochemical and morphological characteristics of the adsorbed matrix. J Biomed Mater Res A (2003) 0.81
HI 6 human serum albumin nanoparticles--development and transport over an in vitro blood-brain barrier model. Toxicol Lett (2011) 0.81
Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. J Drug Target (2005) 0.81
Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells. J Control Release (2013) 0.81
Crystallisation of estradiol containing TDDS determined by isothermal microcalorimetry, X-ray diffraction, and optical microscopy. Eur J Pharm Biopharm (2003) 0.80
Pharmacological activity of DTPA linked to protein-based drug carrier systems. Biochem Biophys Res Commun (2004) 0.79
Determination of the physical state of norethindrone acetate containing transdermal drug delivery systems by isothermal microcalorimetry, X-ray diffraction, and optical microscopy. Eur J Pharm Biopharm (2004) 0.79
Functionalized (poly(ɛ-caprolactone))₂-poly(ethylene glycol) nanoparticles with grafting nicotinic acid as drug carriers. Int J Pharm (2011) 0.79
Coupling of the antitumoral enzyme bovine seminal ribonuclease to polyethylene glycol chains increases its systemic efficacy in mice. Anticancer Drugs (2002) 0.79
Biomimetically mineralized salmon collagen scaffolds for application in bone tissue engineering. Biomacromolecules (2012) 0.79
Incorporation of obidoxime into human serum albumin nanoparticles: optimisation of preparation parameters for the development of a stable formulation. J Microencapsul (2010) 0.79
Physico-chemical characterisation of cationic DOTAP liposomes as drug delivery system for a hydrophilic decapeptide before and after freeze-drying. Eur J Pharm Biopharm (2011) 0.79
Effect of glycerol-L-lactide coating polymer on bone ingrowth of bFGF-coated hydroxyapatite implants. J Control Release (2004) 0.79
Modification of collagen in vitro with respect to formation of Nepsilon-carboxymethyllysine. Int J Biol Macromol (2008) 0.79
Investigation of polymer and nanoparticle properties with nicotinic acid and p-aminobenzoic acid grafted on poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) via click chemistry. Bioconjug Chem (2011) 0.78
Enteric coating derived from marine sponge collagen. Drug Dev Ind Pharm (2009) 0.78
Chitosan(PEO)/silica hybrid nanofibers as a potential biomaterial for bone regeneration. Carbohydr Polym (2013) 0.78
Biological functionalization of dental implants with collagen and glycosaminoglycans-A comparative study. J Biomed Mater Res B Appl Biomater (2011) 0.78
Characterization of collagen II fibrils containing biglycan and their effect as a coating on osteoblast adhesion and proliferation. J Mater Sci Mater Med (2007) 0.77
Influence of modified extracellular matrices on TI6AL4V implants on binding and release of VEGF. J Biomed Mater Res A (2006) 0.77
Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: preparation, characterisation, drug release, cytotoxicity and therapeutic effect on colorectal cancer cells. J Microencapsul (2012) 0.77